FDA opens US to Lyrica generics
daneger / iStockphoto.com
The US Food and Drug Administration (FDA) has granted Pfizer paediatric exclusivity for Lyrica (pregabalin), extending the period of US market exclusivity for the drug by six months.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, US Food and Drug Administration, Lyrica, pregabalin, patent extension, market exclusivity, paediatric exclusivity, patent expiry